Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PAHC 
Phibro Animal Health Corporation (PAHC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: PAHC (4-star) is a STRONG-BUY. BUY since 39 days. Profits (28.23%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $23.5
1 Year Target Price $23.5
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 2 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 77.49% | Avg. Invested days 54 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.22B USD | Price to earnings Ratio 38.75 | 1Y Target Price 23.5 |
Price to earnings Ratio 38.75 | 1Y Target Price 23.5 | ||
Volume (30-day avg) 4 | Beta 0.74 | 52 Weeks Range 16.08 - 31.53 | Updated Date 07/9/2025 |
52 Weeks Range 16.08 - 31.53 | Updated Date 07/9/2025 | ||
Dividends yield (FY) 1.88% | Basic EPS (TTM) 0.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 2.67% | Operating Margin (TTM) 11.39% |
Management Effectiveness
Return on Assets (TTM) 6.26% | Return on Equity (TTM) 11.86% |
Valuation
Trailing PE 38.75 | Forward PE 10.57 | Enterprise Value 1972016954 | Price to Sales(TTM) 1.03 |
Enterprise Value 1972016954 | Price to Sales(TTM) 1.03 | ||
Enterprise Value to Revenue 1.66 | Enterprise Value to EBITDA 15.97 | Shares Outstanding 20367600 | Shares Floating 20194654 |
Shares Outstanding 20367600 | Shares Floating 20194654 | ||
Percent Insiders 0.59 | Percent Institutions 105.25 |
Upturn AI SWOT
Phibro Animal Health Corporation
Company Overview
History and Background
Phibro Animal Health Corporation was founded in 1916 as Philipp Brothers, a global trading firm. It evolved to focus on animal health and nutrition. In 2014, it became a publicly traded company.
Core Business Areas
- Animal Health: Develops, manufactures, and markets a broad range of products for livestock and poultry, including nutritional specialty products, feed additives, and animal health products.
- Nutritional Specialty Products: Provides specialty ingredients for animal nutrition, including mineral nutrition and feed safety products.
- Performance Alternatives: Alternative technology platforms designed to help customers improve animal productivity and improve animal health.
Leadership and Structure
Jack C. Bendheim is the Chairman, and Damien Martin is the Chief Executive Officer. The company operates with a structured leadership team across its various business segments and corporate functions.
Top Products and Market Share
Key Offerings
- Medicated Feed Additives (e.g., BMD): Antibacterial feed additives used to improve growth performance and prevent disease in livestock and poultry. Market share varies by region and product, but Phibro is a significant player. Competitors include Elanco Animal Health (ELAN), Zoetis (ZTS), and Boehringer Ingelheim.
- Nutritional Specialty Products (e.g., OmniGen): A nutritional supplement designed to support immune function and overall health in dairy cows. Estimated revenue varies by quarter, but it is a key product. Competitors include Cargill and ADM.
- Performance Alternatives: Alternative technology platforms designed to help customers improve animal productivity and improve animal health. Competitors include DSM (DSM), Novozymes (NVZMY), and Chr. Hansen (CHR). Market share is growing.
Market Dynamics
Industry Overview
The animal health industry is driven by increasing global demand for animal protein, growing awareness of animal health and welfare, and the need to improve feed efficiency. The market is growing with increased regulation around antibiotic use.
Positioning
Phibro holds a strong position in the animal health market due to its diversified product portfolio, global distribution network, and established relationships with producers. Its competitive advantage lies in its expertise in animal nutrition and disease prevention.
Total Addressable Market (TAM)
The global animal health market is estimated to be over $50 billion and growing. Phibro is well-positioned to capture a portion of this market with its diverse product offerings and global reach.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Global distribution network
- Strong relationships with producers
- Expertise in animal nutrition and disease prevention
- Strong cash flow generation
Weaknesses
- Reliance on regulatory approvals
- Exposure to commodity price fluctuations
- Geographic concentration in certain markets
- Patent expiration of key products
Opportunities
- Expanding into emerging markets
- Developing innovative products
- Acquiring complementary businesses
- Increasing demand for animal protein
Threats
- Increasing competition
- Changing regulations
- Disease outbreaks
- Economic downturns
Competitors and Market Share
Key Competitors
- ELAN
- ZTS
- MRK
- Bayer (BAYRY)
Competitive Landscape
Phibro faces intense competition from larger animal health companies. Its competitive advantage lies in its diversified product portfolio and expertise in animal nutrition. However, the larger market capitalization and R&D spending of firms such as Zoetis, Elanco and Bayer puts PAHC at a distinct disadvantage when developing and marketing new products.
Major Acquisitions
APC Inc
- Year: 2021
- Acquisition Price (USD millions): 45.4
- Strategic Rationale: Expanded Phibro's portfolio of nutritional specialty products and strengthened its presence in the swine market.
Growth Trajectory and Initiatives
Historical Growth: Historically, Phibro has grown through organic expansion and acquisitions. Growth has been driven by increased demand for animal protein and growing awareness of animal health.
Future Projections: Analyst estimates vary, but generally project continued growth driven by global demand for animal protein and strategic acquisitions.
Recent Initiatives: Recent initiatives include expanding into new markets, developing innovative products, and acquiring complementary businesses.
Summary
Phibro Animal Health Corporation is a global animal health company with a diversified product portfolio and a strong presence in key markets. The company is benefiting from increased demand for animal protein, but faces challenges from competition and regulatory changes. It is growing and should be considered a good company to hold. The companies continued strength in new performance technologies will also bode well for its future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Phibro Animal Health Corporation
Exchange NASDAQ | Headquaters Teaneck, NJ, United States | ||
IPO Launch date 2014-04-11 | Chairman, President & CEO Mr. Jack Clifford Bendheim | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1940 | Website https://www.pahc.com |
Full time employees 1940 | Website https://www.pahc.com | ||
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.